Oncology Xagena
Non–small-cell lung cancer ( NSCLC ) harboring the anaplastic lymphoma kinase gene ( ALK ) rearrangement is sensitive to the ALK inhibitor Crizotinib ( Xalkori ), but resistance invariably develops. ...
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs Crizotinib ( Xalkori ) in untreated, advanced / metastatic anaplastic lymphoma kinase- ...
